Payment overview · 2025
General Payments
$385.86
11 reported records · 7 companies
Healthcare provider profile · identity verified
William Mark Haynes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOMER, LA · NPI 1184735151
Verified facts
What the public records show
CMS Open Payments records show William Mark Haynes, M.D. received $385.86 in general payments during 2025 across 11 reported records.
Ardelyx, Inc. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $125.00 | 32.4% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $75.48 | 19.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.74 | 15.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.31 | 12.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.35 | 9.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.86 | 6.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.12 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $385.86 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $75.48 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1011 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 114 |
| Losartan Potassium | Losartan Potassium | 343 | 77 |
| Alprazolam | Alprazolam | 320 | 44 |
| Gabapentin | Gabapentin | 312 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 55 |
| Furosemide | Furosemide | 220 | 45 |
| Omeprazole | Omeprazole | 187 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 45 |
| Potassium Chloride | Potassium Chloride | 175 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 27 |
| Pregabalin | Pregabalin | 148 | 28 |
| Lisinopril | Lisinopril | 141 | 30 |
| Meloxicam | Meloxicam | 135 | 24 |
| Metformin Hcl | Metformin Hcl | 125 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 17 |
| Diazepam | Diazepam | 120 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 34 |
| Atenolol | Atenolol | 113 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 24 |
| Carvedilol | Carvedilol | 108 | 26 |
| Eliquis | Apixaban | 100 | 19 |
| Clonazepam | Clonazepam | 98 | 14 |
| Simvastatin | Simvastatin | 98 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 15 |
| Donepezil Hcl | Donepezil Hcl | 91 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 16 |
| Celecoxib | Celecoxib | 82 | 16 |
| Tramadol Hcl | Tramadol Hcl | 75 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 17 |
| Sertraline Hcl | Sertraline Hcl | 70 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | suppressed |
| Allopurinol | Allopurinol | 65 | 15 |
| Montelukast Sodium | Montelukast Sodium | 63 | 16 |
| Trazodone Hcl | Trazodone Hcl | 63 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 59 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 44 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | suppressed |
| Spironolactone | Spironolactone | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 37 |
| Ozempic | Semaglutide | 45 | suppressed |
| Fluconazole | Fluconazole | 43 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Mupirocin | Mupirocin | 42 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Finasteride | Finasteride | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 31 |
| Linzess | Linaclotide | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 32 | 31 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 14 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 23 | 11 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Sucralfate | Sucralfate | 17 | 12 |
| Sulindac | Sulindac | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | 11 |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $385.86 · 11 records | Ardelyx, Inc. | Auvelity, COBENFY, IBSRELA, INGREZZA, Kerendia, REXULTI, Zunveyl | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error